Journal
EUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume 25, Issue 5, Pages 407-414Publisher
ELSEVIER
DOI: 10.1016/j.ejim.2014.03.005
Keywords
Exenatide; Exenatide once weekly; GLP-1 receptor agonists; Liraglutide; Lixisenatide; Type 2 diabetes
Categories
Funding
- Novo Nordisk Fonden [NNF12OC1015904] Funding Source: researchfish
Ask authors/readers for more resources
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone, secreted in response to ingestion of nutrients, and has important effects on several of the pathophysiological features of type 2 diabetes (T2D). The effects include potentiation of insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and suppression of appetite. In circulation, GLP-1 has a half-life of approximately 2 min due to rapid degradation by the enzyme dipeptidyl peptidase 4 (DPP-4). Because of this short half-life GLP-1 receptor (GLP-1R) agonists, resistant to degradation by DPP-4 have been developed. At the moment four different compounds are available for the treatment of T2D and many more are in clinical development. These compounds, although all based on the effects of native GLP-1, differ with regards to structure, pharmacokinetics and size, which ultimately leads to different clinical effects. This review gives an overview of the clinical data on GLP-1R agonists that have been compared in head-to-head studies and focuses on relevant differences between the compounds. Highlighting these similarities and differences could be beneficial for physicians in choosing the best treatment strategy for their patients. (C) 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available